AKR.L Share News (AKR)

AKR.L Information

There is currently no data for AKR

DIRECTOR DEALINGS: Akers Biosciences Chief Executive Buys First Shares

Thu, 26th May 2016 16:27

LONDON (Alliance News) - Akers Biosciences Inc on Thursday said Chief Executive John Gormally on Tuesday made five separate share purchases, and now holds 2,500 shares in the company.

Gormally purchased 69 shares at USD2.19 per share, 1,000 shares at USD2.20 per share, 100 shares at USD2.23 per share, 200 shares at USD2.24 per share and 1,131 shares at USD2.25 shares.

Following the transactions, Gormally holds 2,500 shares, or a 0.05% stake, in Akers Biosciences.

Shares in Akers Biosciences were untraded on Thursday, having last traded at 131.00 pence.

By Hannah Boland; hannahboland@alliancenews.com; @Hannaheboland

More News

6 Oct 2015 08:03

Akers Biosciences To Launch Two New Health Breath Tests

30 Sep 2015 09:13

Akers Biosciences Signs Four More Distribution Deals

14 Sep 2015 15:30

Akers Biosciences launches ketosis fat-burning breath test via Amazon

(ShareCast News) - Akers Biosciences has begun to make direct sales of its disposable breath ketone test, Metron, through the Amazon website and via the company's online sales portal. The medical device company said the Metron Breath Ketone Test, which is part of its health and wellness line, is the

14 Sep 2015 07:07

Akers Bioscience Launches Disposable Breath Ketone Test Metron

18 Aug 2015 11:28

Akers Biosciences plummets as interim loss widens

(ShareCast News) - Akers Biosciences plummeted after the medical device company said its pre-tax loss widened in the first half as revenue declined. Akers posted a pre-tax loss of $3.41m for the six months ended 30 June, wider than the $1.1m loss in the same period last year. This included a one-tim

18 Aug 2015 11:08